Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by prophetoffactzon Jan 15, 2023 6:38pm
79 Views
Post# 35224531

RE:RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

RE:RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

Metastatic glioblastoma

Last revised by Anthony Zhewei Liu on 07 Jan 2023

Metastatic glioblastoma is a rare progression of glioblastoma, with an incidence of 0.4-0.5% of all glioblastoma cases. The locations can be extraneural, such as leptomeninges and dural venous sinuses, or both extraneural and extracranial, such as solid organs and lymph nodes.

In a recent case series in the United States, the top five regions of metastases in order of frequencies are bone, lymph node (thoracic and cervical), lung, leptomeninges, and soft tissue 1.

The median time from diagnosis of the primary glioblastoma to metastasis and from detection of metastasis to death was 8.5 months and 1.5 months, respectively. Patients with lung metastases carry the worst prognosis 2.

Male gender, young age, and proximity to the ventricular system are identified as risk factors for metastasis 3.


Boomskid wrote: Correct, poof. And CED is intracranial. What is your understanding of diffuse target engagement with convection-enhanced delivery?

Does CED have prophylactic value for diffuse tumours or is it necessary to wait for larger solid tumours grow before CED becomes an option?

And why would intracranial delivery be used when a simple injection of an xB3-Drug would deliver its payload throughout the CNS rather than locally as we see with CED?

jd


<< Previous
Bullboard Posts
Next >>